The company reported significant commercial momentum with 291% year-over-year growth in TMS center customer adoption. The expansion demonstrates successful execution of growth strategy, increasing market penetration, and validation of its AI-driven diagnostic platform. The development of novel biomarkers and partnerships further support positive trajectory.
The company announced a strategic partnership with a well-established longevity leader, received FDA Advisory Committee support for peptide compounding eligibility, and is expanding its clinical applications for its FDA-cleared technology. The collaboration positions Firefly to scale its AI-powered brain biomarker platform across Next Health's expanding clinic network.
Articles that tag AIFF but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
